#37: Lipids, PCSK9, and ezetimibe: Lower is better.
Published May 1, 2017
68 min
    Add to queue
    Copy URL
    Show notes

    Learn the latest in lipid lowering therapy in this extensive discussion with Dr. Paul S. Jellinger, MD, MACE, Professor of Medicine at the University of Miami and Chair of the writing committee for the American Association of Clinical Endocrinologists (AACE) 2017 Guidelines for the Management of Dyslipidemia and Prevention of Cardiovascular Disease (CVD). Topics include ezetimibe, PCSK9, FOURIER trial, statin myopathy, CoQ10, fish oil, fibrates and more. For a more basic discussion of dyslipidemia check out episode #10.

    Full show notes are available at http://thecurbsiders.com/podcast

    Join our newsletter mailing list. Rate us on iTunes, recommend a guest or topic and give feedback at thecurbsiders@gmail.com.

    Time Stamps

    00:00 Intro

    03:10 Rapid fire questions

    08:15 Dyslipidemia defined

    10:26 Classifying dyslipidemia

    13:21 Diagnosing Familial Hypercholesterolemia

    17:48 A difficult lipid case discussed

    22:40 Lp (a), Apo B and LDL particle concentration

    28:40 What labs to order

    31:31 ACC/AHA versus other risk scores

    38:21 IMPROVE-IT

    41:35 Non-statin medications discussed

    45:05 Hypertriglyceridemia fibrates and fish oil

    48:25 How often to check the lipid panel

    49:58 Statin Myopathy and CoQ10

    54:17 FOURIER, PCSK9 and very low LDLs

    59:43 Extreme risk category discussed

    62:34 Is plaque regression possible?

    64:12 Take home points

    67:08 Outro

    Tags: assistant, care, cholesterol, doctor, education family, fish oil, foam, foamed, health, hospitalist, hospital, internal, internist, ldl, lipid, medicine, medical, myopathy, nurse, pcsk9, physician, practitioner, primary, statin, resident, student

        0:00:00 / 0:00:00